new glp 1 agonist novo nordisk GLP-1s for Alzheimer's: announces trial conclusion Novo Nordisk says Alzheimer's trial

Standard review would push the timeline into early 2027

Based on the function of Tregs and their ability to induce cytokine immunosuppression, researchers consider treating AR by increasing IL-10, TGF-, and IgG4 levels and Treg cell counts to induce immune tolerance [105]

doi:10.1016/j.actbio.2014.01.020

Cardiovasc Drugs 20, 363372

L-ergothioneine and its combination with metformin attenuates renal dysfunction in type-2 diabetic rat model by activating Nrf2 antioxidant pathway

(2) developing synthesis protocols and quality control standards compliant with Good Manufacturing Practice (GMP) for clinical translation